Bharat Book Bureau

Global Diabetes Market Trends & Future Forecast

Press Release   •   Sep 06, 2010 14:10 IST

HTML clipboardGlobal Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

“Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” report provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering: ( http://www.bharatbook.com/detail.asp?id=144402&rt=Global-Diabetes-Market-Trends-Future-Forecast-Diabetes-Drug-Anti-Diabetic-DrugInsulin-DPP-IV-GLP-1.html )

• Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
• Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
• Region wise Diabetes Health Expenditure and Mortality
• Top 10 Countries Diabetes Population and Future Forecast
• Top 5 Countries Diabetes Drug Market and Future Forecast
• Top 7 Countries Insulin Market and Future Forecast
• Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market
• Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market
• Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market
• Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market

Research Highlights

• USA controls more than 50% of the total Diabetes Drug market share in 2009
• Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
• China will have the second highest Insulin market share by 2012 replacing Germany
• DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
• GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
• Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.
• Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
• Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US$ 4 Billion by 2017
• Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists
• China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
• Japan Insulin market is expected to be more than US$ 1 Billion by 2010

For more information kindly visit :   http://www.bharatbook.com/detail.asp?id=144402&rt=Global-Diabetes-Market-Trends-Future-Forecast-Diabetes-Drug-Anti-Diabetic-DrugInsulin-DPP-IV-GLP-1.html

Related Reports

India Diabetes Care Devices Market Outlook to 2016
http://www.bharatbook.com/detail.asp?id=94991&rt=India-Diabetes-Care-Devices-Market-Outlook-to-2016.html

The Future of the Diabetes Care Devices Market to 2016 - The Key Demand Drivers Remain Intact
http://www.bharatbook.com/detail.asp?id=130194&rt=The-Future-of-the-Diabetes-Care-Devices-Market-to-2016-The-Key-Demand-Drivers-Remain-Intact.html

Or

Contact us at

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com

HTML clipboard

Bharat Book Bureau is the leading business information aggregator providing market research reports and online databases. Bharatbook is also into the business of marketing conferences worldwide and undertakes custom research. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies.